GATA3 polyclonal antibody
- Known as:
- GATA3 pab (anti-)
- Catalog number:
- PAB18658
- Product Quantity:
- 100 ug
- Category:
- -
- Supplier:
- Abno
- Gene target:
- GATA3 polyclonal antibody
Related genes to: GATA3 polyclonal antibody
- Gene:
- GATA3 NIH gene
- Name:
- GATA binding protein 3
- Previous symbol:
- -
- Synonyms:
- HDR
- Chromosome:
- 10p14
- Locus Type:
- gene with protein product
- Date approved:
- 1992-11-03
- Date modifiied:
- 2016-10-05
Related products to: GATA3 polyclonal antibody
Related articles to: GATA3 polyclonal antibody
- Papillary renal neoplasm with reverse polarity (PRNRP) has been proposed as a distinct subtype of renal cell neoplasm with recurrent KRAS mutations and indolent behavior. However, its epigenetic landscape is poorly understood. In this study, 12 PRNRPs and a PRNRP initially diagnosed as "papillary adenoma" were analyzed. All 13 cases underwent targeted next-generation sequencing for driver mutations. Eleven PRNRPs were profiled using the Illumina MethylationEPIC array and compared with a reference cohort of 71 common renal cell tumors. KRAS mutations were identified in 12 of 13 (92%) cases of PRNRP. Copy-number analysis from methylation profiling showed that 9 of 11 (82%) PRNRPs lacked copy-number changes. Two cases showed a focal loss of chromosome 8 and a gain of chromosome 16, respectively. Unsupervised clustering based on methylation data showed that PRNRPs form a distinct epigenetic group, separate from papillary renal cell carcinomas (pRCCs) and other major renal tumors, but with the closest affinity to clear cell papillary renal cell tumors. In addition, DNA methylation analysis suggested PRNRP may arise from the distal nephron, in contrast to pRCC, which appears to recapitulate proximal tubules. These findings support PRNRP as a subtype of renal cell neoplasm with a distinct epigenetic signature. - Source: PubMed
Publication date: 2026/06/17
Park KyungWang YuxiuKim KisongSerrano JonathanChen FeiVasudevaraja VarshiniFeng XiaojunMirsadraei LeiliSnuderl MatijaDeng Fang-Ming - CD4 T cells are central to adaptive immunity, with GATA binding protein 3 (Gata-3) acting as a key transcription factor for Th subset differentiation. This study aimed to characterize Gata-3 in flounder (Paralichthys olivaceus) and investigate its role in CD4 T cell differentiation via its zinc finger domains (ZnFs). Flounder Gata-3 contains two conserved C4-type ZnFs and showed peak expression in gills. Immunofluorescence assays suggested that Gata-3 located in gill leukocytes, co-localized with CD4-1/CD4-2 cells but not CD8 or IgM cells. Under in vitro Th2 differentiation, the proportion of CD4 cells increased from 15.77 ± 2.59% to 21.13 ± 1.92%. Concurrently, gata-3, jak3, stat6, il-10, and c-maf were significantly upregulated, while Th1-related genes (e.g., t-bet, ifn-γ) were significantly downregulated. Overexpression of Gata-3 in 293T cells significantly inhibited the promoters of t-bet and ifn-γ. Meanwhile, a recombinant plasmid of Gata-3 without the ZnFs was constructed and transfected into HINAE cells; this experiment that only Gata-3 was significantly upregulated, while no significant changes were observed in the expression of t-bet, ifn-γ, stat4, or il-12rβ. Furthermore, two mutants of Gata-3 lacking the C- or N-terminal ZnF were constructed, but only the mutant lacking the C-terminal ZnF exhibited no inhibition on t-bet and ifn-γ promoters. In conclusion, Gata-3 promotes Th2 differentiation while inhibiting the Th1 pathway in flounder by directly repressing T-bet and ifn-γ, a process critically mediated by its C-terminal ZnF. This study provides new insights into the evolutionary conservation of T cell immune regulation in teleosts. - Source: PubMed
Publication date: 2026/06/15
Duan ZhixiangHe ZiyangTang XiaoqianSheng XiuzhenChi HengXing JingZhan Wenbin - Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease characterised by loss of immune tolerance and chronic inflammation, but its molecular pathogenesis remains incompletely understood. In this work we examine whether immune regulatory transcripts and pathways are recurrently detectable across heterogeneous publicly available SLE transcriptomic datasets, and we explore one of the recurrent pathways with a kinetic systems-biology model. We analyzed one microarray dataset (E-GEOD-46923, profiled on Affymetrix HG-U133A and HG-U133B), two bulk RNA-seq datasets (E-MTAB-7145, E-MTAB-11919), and two single-cell RNA-seq datasets (GSE135779, GSE163121) using a unified differential-expression criterion (|log2 fold change|≥ 1, Benjamini-Hochberg adjusted p-value < 0.05). KEGG pathway enrichment was performed with a per-dataset background gene universe. A mass-action kinetic model of Th1/Th2 differentiation was constructed in MATLAB SimBiology, and global sensitivity analysis was performed using the variance-based Sobol method. Across the heterogeneous datasets, CD53, IFITM1, and RPL11 were recurrently identified as differentially expressed transcripts, and the Th1/Th2 cell differentiation pathway, together with related cytokine-cytokine receptor and JAK-STAT pathways, emerged as a recurrent immune-regulatory signal. Systems-biology simulation under SLE-derived initial conditions predicted atypical IL-2 and GATA3 expression dynamics, which is consistent with, but does not by itself prove, the cytokine-signalling dysregulation reported in SLE. Sobol sensitivity analysis identified IL-4 and the modelled co-stimulatory and Notch ligand species (CDN1-6 and Jagged1/2) as the largest non-additive regulators of IL-2 in the model. Overall, this work integrates transcriptomic recurrence analysis with kinetic modelling to generate testable hypotheses regarding immune regulatory dysfunction in SLE. - Source: PubMed
Publication date: 2026/06/15
Saleem KashifParacha Rehan ZafarKhalid LintaManzoor AyeshaNisar MaryumMurad DidarDin Nazar MuhammadAmir Afreenish - Two traditional Chinese medicine (TCM) formulas are Guilu Erxian Glue (GEG) and Danggui Buxue Tang (DBT). Their combination, Modified Guilu Erxian Glue (MGEG), is used to treat aplastic anemia (AA). This study aims to clarify how MGEG restores immune tolerance in AA mice. Specifically, we studied whether MGEG can regulate the differentiation and maturation of T cell lineage by regulating the transcription of miR-146a to rebuild the stable state of bone marrow immune microenvironment, inhibit the immune response mediated by T helper (Th)1 cells, and enhance the immunosuppressive function of regulatory T cells (Tregs). - Source: PubMed
Publication date: 2026/05/29
Zhang YingkaiBai DongtianSun SongLiu WeiZhang PingxinNiu JingminSang JinghaoLi DongyangLiu JuanChai Limin - Occult breast cancer (OBC) is a rare clinical entity characterized by metastatic disease in the absence of an identifiable primary breast lesion. Metastases to the thyroid gland are rare. Breast carcinoma infrequently metastasizes to the thyroid, and cases arising from OBC are exceptionally uncommon, posing a significant diagnostic challenge. We report the case of a 63-year-old woman with no prior history of malignancy who presented with diffuse abdominal pain, headache, and neck stiffness. A thyroid nodule was identified during diagnostic evaluation. Ultrasonography demonstrated a hypoechoic lesion with irregular margins, and core needle biopsy suggested malignancy. Immunohistochemical (IHC) analysis showed positivity for estrogen receptor (ER), progesterone receptor (PR), mammaglobin, and GATA3, with negativity for thyroglobulin (TG), PAX8, and thyroid transcription factor-1 (TTF-1), supporting a breast origin. Mammography and breast ultrasonography were negative. Breast magnetic resonance imaging (MRI) was not performed due to rapid clinical deterioration. During hospitalization, she developed a generalized tonic-clonic seizure. Imaging revealed multiple brain metastases, indicating advanced disease. This case underscores the diagnostic complexity of thyroid lesions and highlights the necessity of considering metastatic disease, particularly in the context of OBC. Accurate diagnosis requires comprehensive histopathological assessment supported by immunohistochemical profiling to reliably distinguish metastatic involvement from primary thyroid malignancies. Prompt recognition is crucial to inform optimal therapeutic decision-making in these challenging clinical scenarios. - Source: PubMed
Publication date: 2026/05/13
Milonaki DespoinaPantoula PanagiotaProvatas IoannisFourlopoulou ArgyroSinou Nikoleta